Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.

@article{Hames2016CorrelationBK,
  title={Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.},
  author={Megan L. Hames and Heidi Chen and Wade T. Iams and Jonathan L Aston and Christine M Lovly and Leora A Horn},
  journal={Lung cancer},
  year={2016},
  volume={92},
  pages={29-34}
}
OBJECTIVES KRAS mutations are the most commonly found mutations in patients with non-small cell lung cancer (NSCLC) adenocarcinoma histology. The clinical implications of KRAS mutations in patients with advanced NSCLC are not well defined. We sought to determine if there is a correlation between KRAS mutation status, response to cytotoxic chemotherapy, and survival in patients with metastatic or recurrent NSCLC. MATERIALS AND METHODS Patients with metastatic or recurrent NSCLC and tumor… CONTINUE READING